Former Chief Executive Officer · AGIOS PHARMACEUTICALS, INC. (AGIO)

Jacqualyn Fouse

A named executive officer of AGIOS PHARMACEUTICALS in every fiscal year CompBrief holds from FY2019 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$4,911,049

Salary $466,761Stock awards $1,408,188

FY2021: $6,519,427

2nd of 8 named executive officers at Agios Pharmaceuticals by FY2022 total.

8 named officers on file for AGIOS PHARMACEUTICALS, FY2022

Jacqualyn Fouse’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 10 equity grants, each cited to its filing
  • AGIO’s disclosed peer group of 14 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how AGIOS PHARMACEUTICALS’s whole pay program stands against its peers

  • AGIOS PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AGIO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2023 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Jacqualyn Fouse’s full pay file as a PDF — free

More than this page: up to 10 years of Jacqualyn’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Jacqualyn Fouse compensation by year

AGIOS PHARMACEUTICALS Summary Compensation Table · all 4 fiscal years held
In US dollars, as AGIOS PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2019FY2020FY2021FY2022
Salary$664,583$746,750$760,000$466,761
Bonus$0$0$0$0
Stock awards$2,538,474$1,751,340$0$1,408,188
Option awards$12,875,608$4,593,651$5,202,524$2,732,839
Non-equity incentive$424,125$509,657$543,400$292,950
Pension and deferred compensation$0$0$0$0
All other$105,204$10,577$13,503$10,311
Total$16,607,994$7,611,975$6,519,427$4,911,049

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: AGIOS PHARMACEUTICALS, INC. DEF 14A filed April 26, 2023, accession 0001193125-23-118490, and prior-year filings. Open the filing on EDGAR.

How this page was built: the AGIOS PHARMACEUTICALS, INC. filed document, accession 0001193125-23-118490. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2023.

$16.6M
$7.6M
$6.5M
$4.9M
FY19
FY20
FY21
FY22
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2022 year-end
TypeUnvested unitsValue at year-endExercise price
RSU47,800$1,342,224—
RSU11,333$318,231—
Option14,598—$53.87
Option170,000—$29.46
Option88,296—$56.68
Option39,962—$51.51

Per the Outstanding Equity Awards at Fiscal Year-End table in AGIOS PHARMACEUTICALS, INC.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

29 Form 4 lines since the FY2022 proxy (filed April 26, 2023)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-06-18Grant or award derivative—14,950$0.0014,950
2026-06-18Exercise or conversion derivative—2,816$0.000
2026-06-18Grant or award derivative—2,927$0.002,927
2026-06-18Exercise or conversion—2,816$0.00154,156
2025-06-20Exercise or conversion—2,120$0.00151,340
2025-06-20Exercise or conversion derivative—2,120$0.000
2025-06-18Grant or award derivative—15,768$0.0015,768
2025-06-18Grant or award derivative—2,816$0.002,816

The 8 most recent of 29 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

AGIOS PHARMACEUTICALS’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Brian GoffChief Executive Officer$11,744,447
Jacqualyn Fouse · this pageFormer Chief Executive Officer$4,911,049
Cecilia JonesChief Financial Officer$2,910,926
Richa PoddarFormer Chief Commercial Officer$1,926,456
Bruce CarFormer Chief Scientific Officer$1,852,384
Sarah GheuensChief Medical Officer, Head of Research & Development$1,846,903
James BurnsChief Legal Officer$1,738,025
Jonathan BillerFormer Chief Financial Officer, Head of Corporate Affairs$1,478,067

Board service

AGIOS PHARMACEUTICALS board · FY2021–FY2025
Director compensation in US dollars, as AGIOS PHARMACEUTICALS reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$92,500$99,968$299,689$0$492,157
FY2024$87,500$89,994$266,287$0$443,781
FY2023$87,500$89,985$269,767$0$447,252
FY2022—$47,800$170,000$0—
FY2021—————

Each year as the company reported it in AGIOS PHARMACEUTICALS's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: AGIOS PHARMACEUTICALS pays directors a $50,000 cash retainer and $400,000 in RSUs/Options. As stated in AGIOS PHARMACEUTICALS's FY2025 proxy.

Committees

Science and Technology

The full AGIOS PHARMACEUTICALS compensation record

free company brief

This page is one person within AGIOS PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are AGIOS PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Jacqualyn Fouse's compensation dossier · One-time report. No refunds.